T1	Participants 551 656	small studies have demonstrated a reduction in the degree of MVO utilising a variety of vasoactive agents
T2	Participants 1098 1145	Patients presenting within 6 h of onset of STEM
T3	Participants 1451 1515	All receive Bivalirudin anticoagulation and thrombus aspiration.
T4	Participants 1877 1915	The study aims to recruit 240 patients
